Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Weill Medical College of Cornell University8 enrolled

Overview

Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diffuse Large B-cell Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have histologically or cytologically confirmed diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma * Patients must have received no prior anti-lymphoma therapy. * Age \>18 years. * Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients who have known HIV infection. * Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.

Locations (1)

Weill Cornell Medical College

Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes